TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of General Internal Medicine
Division of Thoracic Medicine
更新時間：2024-03-21
楊志新Yang, James Chih-Hsin
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
63Publications
1
Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 Jan;16(1):162-168. doi: 10.1016/j.jtho.2020.09.015. Epub 2020 Oct 15. PMID: 33069888.
2
Kok PS, Lee K, Lord S, Yang JC, Rosell R, Goto K, John T, Wu YL, Mok TSK, Lee CK. Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. Lung Cancer. 2021 Apr;154:113-117. doi: 10.1016/j.lungcan.2021.02.027. Epub 2021 Feb 22. PMID: 33647577.
3
Griesing S, Liao BC, Yang JC. CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer. Anticancer Res. 2021 Mar;41(3):1231-1242. doi: 10.21873/anticanres.14880. PMID: 33788714.
4
Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 Feb 15;27(4):992-1002. doi: 10.1158/1078-0432.CCR-20-1690. Epub 2020 Oct 12. PMID: 33046516; PMCID: PMC8793125.
5
Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, Yen SH, Wu YH, Yang JC, Liao BC, Hsia TC, Chen YM. Lung Cancer in Republic of China. J Thorac Oncol. 2021 Apr;16(4):519-527. doi: 10.1016/j.jtho.2020.10.155. PMID: 33781442.
6
Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang JC. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2021 Jan 13;13(2):272. doi: 10.3390/cancers13020272. PMID: 33450879; PMCID: PMC7828377.
7
Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer. 2021 Apr;154:92-98. doi: 10.1016/j.lungcan.2021.01.026. Epub 2021 Feb 6. PMID: 33636453.
8
Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. Circulating Exosomal Integrin β3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study. Cancers (Basel). 2021 Jan 20;13(3):380. doi: 10.3390/cancers13030380. PMID: 33498505; PMCID: PMC7864205.
9
Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2021 Mar;17(8):965-977. doi: 10.2217/fon-2020-0951. Epub 2020 Nov 26. PMID: 33242257.
10
Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JCH, Ishii H, Garassino M, de Marinis F, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Xiong H, Bajars M, Ruisi M, Barlesi F. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. J Thorac Oncol. 2021 Aug;16(8):1369-1378. doi: 10.1016/j.jtho.2021.03.009. Epub 2021 Apr 9. PMID: 33845211.
